The increasingly drawn-out play from Sanofi to buy cancer biotech Medivation shows no signs of being settled soon as the biotech’s management continues to push…

Epizyme has nabbed a partner in Roche’s Genentech for its tazemetostat and they are proceeding with a combination trial for the candidate in a subgroup of NHL…

New Enterprise Associates has come in to lead a $44 million Series B round for Annexon Biosciences, which is slated to get the startup through Phase II data in…

Incyte is getting in on one of the hottest tickets in oncology R&D right now--PD-1/PD-L1 checkpoint inhibitors--as it announces a new Phase III combo deal…

Celgene is backing four NCI Cancer Center research hospitals with $50 million in an ambitious new 10-year deal.

Selecta Biosciences expects to get Phase II data for its lead candidate with the $70 million it just raised in an IPO.

Scotland’s trial tech company eClinicalHealth and partners Sanofi, U.K. consultant and ad company Langland and Finnish healthcare tech firm Mendor have posted…

Slovakian biotech Axon Neuroscience has treated the first patient with its closely watched Alzheimer’s vax AADvac1--which is aiming to be the first disease-…